ArticlePLoS pathogens2016
PSGL-1 on Leukocytes is a Critical Component of the Host Immune Response against Invasive Pneumococcal Disease.
Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Targeting the PSGL-1 glycoprotein in cancer: cellular mechanisms and emerging immunotherapeutic strategies.Immunotherapy advances · 2026Review
- Structure, Function, and Regulation of LytA: TheMicroorganisms · 2025Review
- A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy.Biomarker research · 2024Review
- Low P-Selectin Glycoprotein Ligand-1 Expression in Neutrophils Associates with Disease Activity and Deregulated NET Formation in Systemic Lupus Erythematosus.International journal of molecular sciences · 2023Article
- Defining the versican interactome in lung health and disease.American journal of physiology. Cell physiology · 2022Review
- Neutrophil Recruitment in Pneumococcal Pneumonia.Frontiers in cellular and infection microbiology · 2022Review
- NLRP6 Serves as a Negative Regulator of Neutrophil Recruitment and Function DuringFrontiers in microbiology · 2022Article
- Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains.Antibiotics (Basel, Switzerland) · 2021Article
- Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases.Vaccines · 2021Article
- Vaccination with LytA, LytC, or Pce ofVaccines · 2021Article
- Review
- PSGL-1 Immune Checkpoint Inhibition for CD4Frontiers in immunology · 2021Review
- P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target.Frontiers in immunology · 2021Review
- Article
- Article
- CSF Levels of Elongation Factor Tu Is Associated With Increased Mortality in Malawian Adults WithFrontiers in cellular and infection microbiology · 2020Article
- Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F ofFrontiers in microbiology · 2020Article
- Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus.Future microbiology · 2018Article
- Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract.Antimicrobial agents and chemotherapy · 2018Article
- A compendium and functional characterization of mammalian genes involved in adaptation to Arctic or Antarctic environments.BMC genetics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial uptake by phagocytic cells is a vital event in the clearance of invading pathogens such as Streptococcus pneumoniae. A major role of the P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes against invasive pneumococcal disease is described in this study. Phagocytosis experiments using different serotypes demonstrated that PSGL-1 is involved in the recognition, uptake and killing of S. pneumoniae. Co-localization of several clinical isolates of S. pneumoniae with PSGL-1 was demonstrated, observing a rapid and active phagocytosis in the presence of PSGL-1. Furthermore, the pneumococcal capsular polysaccharide and the main autolysin of the bacterium--the amidase LytA--were identified as bacterial ligands for PSGL-1. Experimental models of pneumococcal disease including invasive pneumonia and systemic infection showed that bacterial levels were markedly increased in the blood of PSGL-1-/- mice. During pneumonia, PSGL-1 controls the severity of pneumococcal dissemination from the lung to the bloodstream. In systemic infection, a major role of PSGL-1 in host defense is to clear the bacteria in the systemic circulation controlling bacterial replication. These results confirmed the importance of this receptor in the recognition and clearance of S. pneumoniae during invasive pneumococcal disease. Histological and cellular analysis demonstrated that PSGL-1-/- mice have increased levels of T cells migrating to the lung than the corresponding wild-type mice. In contrast, during systemic infection, PSGL-1-/- mice had increased numbers of neutrophils and macrophages in blood, but were less effective controlling the infection process due to the lack of this functional receptor. Overall, this study demonstrates that PSGL-1 is a novel receptor for S. pneumoniae that contributes to protection against invasive pneumococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.